First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study
医学
彭布罗利珠单抗
肿瘤科
内科学
安全概况
扩展访问
队列
不利影响
临床试验
免疫疗法
作者
Martin Reck,Jyoti D. Patel,Jhanelle E. Gray,Noemı́ Reguart,Manuel Cobo,José Fuentes Pradera,Enriqueta Felip,Federico Cappuzzo,Edward B. Garon,Joel W. Neal,Sabeen Mekan,Farnoush Safavi,Nelumka Fernando,Marianna Zavodovskaya,Juliane M. Jürgensmeier,Michael Chisamore,Byoung Chul Cho
PDF的下载单位、IP信息已删除
(2025-6-4)
Kao
Copyright
cdercder
Criminology34
GingerF
keven
YifanWang
OK
musen
无极微光
arniu2008
核桃
EastWind
Nole
潇洒的惋清
Nexus
369ninja
sanvva
火星上的菲鹰
lizishu
皖公网安备34019202002308
